IP Library Granted Patent US 11,523,997
Granted Patent B2
US 11,523,997 · App. 16/930,208 · Granted Dec 13, 2022

Method of providing celiprolol therapy to a patient

Inventor: Michael Frank (Gambais, FR)
Assignee: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
A61K31/17A61P9/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,523,997
App. No.
16/930,208
Granted
Dec 13, 2022
Kind
B2
Abstract

The present disclosure relates to the field of treatment of an orphan disease, in particular treatment of vascular Ehlers-Danlos syndrome (vEDS). More specifically, the present disclosure relates to novel up-titration dosage regimens (e.g., escalating dosage regimens) effective for treating vEDS patients with celiprolol.

Claims (15)

1. A method for treating vascular Ehlers-Danlos syndrome, comprising administering to a patient in need thereof an initial daily dose of about 91.25 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, for about 1 month, followed by administering to the patient a second daily dose of about 182.5 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, for about 1 month, followed by administering to the patient a third daily dose of about 273.75 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof, for about 1 month, followed by administering to the patient a fourth daily dose of about 365 mg celiprolol, or an equivalent amount of a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the second daily dose is administered twice daily.

3. The method of claim 2 , wherein the fourth daily dose is administered twice daily.

4. The method of claim 1 , wherein the fourth daily dose is administered for at least 1 year.

5. The method of claim 1 , wherein the fourth daily dose is administered for at least 5 years.

6. The method of claim 1 , wherein the patient is 15-years old or older.

7. The method of claim 1 , wherein the treatment is initiated as soon as vascular EDS is diagnosed, or when the patient is 10 years old.

8. A method for treating vascular Ehlers-Danlos syndrome, comprising administering to a patient in need thereof an initial daily dose of about 100 mg celiprolol hydrochloride for about 1 month, followed by administering to the patient a second daily dose of about 200 mg celiprolol hydrochloride for about 1 month, followed by administering to the patient a third daily dose of about 300 mg celiprolol hydrochloride for about 1 month, followed by administering to the patient a fourth daily dose of about 400 mg celiprolol hydrochloride.

9. The method of claim 8 , wherein the initial daily dose is administered at about 100 mg once daily.

10. The method of claim 8 , wherein the second daily dose is administered at about 100 mg twice daily.

11. The method of claim 8 , wherein the fourth daily dose is administered at about 200 mg twice daily.

12. The method of claim 8 , wherein the fourth daily dose is administered for at least 1 year.

13. The method of claim 8 , wherein the fourth daily dose is administered for at least 5 years.

14. The method of claim 8 , wherein the patient is 15-years old or older.

15. The method of claim 8 , wherein the treatment is initiated as soon as vascular EDS is diagnosed, or when the patient is 10 years old.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: ZEVRA THERAPEUTICS INC. (AS SUCCESSOR IN INTEREST TO NANTAHALA CAPITAL MANAGEMENT, LLC, AS SUCCESSOR IN INTEREST TO SWK FUNDING LLC)
To: ACER THERAPEUTICS INC.
Reel/Frame 067020/0036 →
SECURITY INTEREST Recorded Jul 6, 2023
From: SWK FUNDING LLC; ACER THERAPEUTICS INC
To: NANTAHALA CAPITAL MANAGEMENT, LLC
Reel/Frame 064167/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2022
From: FRANK, MICHAEL
To: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
Reel/Frame 061485/0230 →
SECURITY INTEREST Recorded Mar 11, 2022
From: ACER THERAPEUTICS INC.
To: SWK FUNDING LLC
Reel/Frame 059237/0638 →
Priority Claims (1)
EP 17306890 · Dec 21, 2017 · regional
Continuity (2)
Continuation 16184922 · Nov 8, 2018
Related Publication 20210000770A1 · Jan 7, 2021